Mechanistically, a cancer cell-intrinsic MEK-ERK1/2-SP1 signaling cascade enforces expression and secretion of GM-CSF, an exploitable vulnerability synergistic with the current standard of care treatment for HCC employing VEGF neutralization. The gene discussed is MAPK3; the disease is cancer.